Iterum Therapeutics plc announced that the first patient has been dosed in its Phase 3 clinical trial, known as REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales (REASSURE), comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin(R) (amoxicillin/clavulanate) in adult women with uncomplicated urinary tract infections (uUTI).